



# PROFILES OF ANTIDIABETIC MEDICATIONS



	MET	GLP-1 RA	SGLT-2i	DPP-4i	AGi	TZD (moderate dose)	SU GLN	COLSVL	BCR-QR	INSULIN	PRAML
<b>HYPO</b>	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Moderate/ Severe Mild	Neutral	Neutral	Moderate to Severe	Neutral
<b>WEIGHT</b>	Slight Loss	Loss	Loss	Neutral	Neutral	Gain	Gain	Neutral	Neutral	Gain	Loss
<b>RENAL / GU</b>	Contraindicated if eGFR < 30 mL/min/1.73 m <sup>2</sup>	Exenatide Not Indicated CrCl < 30	Not Indicated for eGFR < 45 mL/min/1.73 m <sup>2</sup>	Dose Adjustment Necessary (Except Linagliptin)  Effective in Reducing Albuminuria	Neutral	Neutral	More Hypo Risk	Neutral	Neutral	More Hypo Risk	Neutral
		Possible Benefit of Liraglutide	Genital Mycotic Infections								
<b>GI Sx</b>	Moderate	Moderate	Neutral	Neutral	Moderate	Neutral	Neutral	Mild	Moderate	Neutral	Moderate
<b>CHF</b>	Neutral	Possible Benefit of Liraglutide	Possible Benefit of Empagliflozin	Possible Risk for Saxagliptin and Alogliptin	Neutral	Moderate	More CHF Risk	Neutral	Neutral	More CHF Risk	Neutral
<b>CARDIAC*</b>			Possible CV Benefit	Possible CV Benefit		Neutral	May Reduce Stroke Risk	?	Benefit	Safe	
<b>ASCVD</b>											
<b>BONE</b>	Neutral	Neutral	Canagliflozin Warning	Neutral	Neutral	Moderate Fracture Risk	Neutral	Neutral	Neutral	Neutral	Neutral
<b>KETOACIDOSIS</b>	Neutral	Neutral	DKA Occurring in T2D in Various Stress Settings	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral	Neutral

■ Few adverse events or possible benefits    
 ■ Use with caution    
 ■ Likelihood of adverse effects    
 ? Uncertain effect    
 \* FDA indication to prevent CVD death in diabetes plus prior CVD events